TwentyTwentyTweets
-
Join 7,195 other subscribers
-
Recent Posts
Pages
Tag Archives: competition
Are pharmaceutical mega-mergers in the public interest?
The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development – R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading
Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology
Tagged 2020health, AstraZeneca, Beecham, Boots, competition, David Jack, Drugs, Glaxo, innovation, Keith Mansford, medicine, merger, Pfizer, pharmaceutical, R&D, Research, Sir David Jack, SmithKline, Smithkline Beecham, Tagamet, takeover
Leave a comment
Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.
David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading
Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care
Tagged 2020health, block-buster, competition, David Cameron, demand, Department of Health, drug pricing system, Drugs, elderly, GP, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, parallel exports, parallel imports, patient, Patients, pharmaceutical, Philosophy and Economics, Politics, PPE, PPRS, pricing, quality of life, R&D, reference price, Research, value-based, value-based pricing, VBP
Leave a comment
Guest Blogspot: Pharmaceutical R & D – the value of radical innovation versus incremental progress
What we really want is affordable products that benefit patients, whether or not they are “innovative” in the usual sense of the word. Scientific innovation is not a medical end in itself. The ultimate aim of pharmaceutical R&D is to … Continue reading
Posted in Business, competition, Department of Health, Drugs, Emerging technologies, Finance, Healthcare, Innovation, NHS, Patients, Pharma, Policy, Research, Technology, Uncategorized
Tagged 2020health, Alderlin, angina, atenolol, beta-blocker, cimetidine, competition, David Jack, definition of innovation, Department of Health, Drugs, Eraldin, government, heart drug, incremental, Inderal, innovation, innovative, James Black, medicine, Michael Rawlins, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, practolol, pricing, pronethalol, propranolol, R&D, ranitidine, Research, Sir David Jack, Sir James Black, Sir Michael Rawlins, Tagamet, Tenormin, ulcer drug, value-based, value-based pricing, Zantac
Leave a comment
The Health and Social Care Bill: Final Stages in Parliament
With opposition to the Health and Social Care Bill having reached new heights, we must look behind the rhetoric and remember basic principles. The most important point to remember is that the NHS exists to provide the best possible, affordable … Continue reading
Posted in Andrew Lansley, Business, Commissioning, competition, David Cameron, Department of Health, GPs, Health Bill, Hospitals, Inequality, NHS, Patient choice, Patients
Tagged 2020health, Andrew Lansley, Bevan, BMA, bureaucracy, Commissioning, competition, David Cameron, Department of Health, efficiency, government, GP, GPs, health, Health Bill, inaccurate media, National Health Service, NHS, NICE, Nye Bevan, Old age, patient, Patients, Responsibility in healthcare
Leave a comment
Guest Blogspot: Misleading, Biased Reporting on the Health and Social Care Bill in the Media
Above all the freedom of the Press is paramount. Censorship or severely restrictive legislation is not an acceptable alternative. We sometimes have to accept the consequences and tolerate a Press that can be wrong, unfair, misleading or more interested in … Continue reading
Posted in Andrew Lansley, competition, David Cameron, Department of Health, equality, Finance, Health Bill, Hospitals, Inequality, NHS, Patients, Private
Tagged 2020health, Andrew Burnham, Andrew lansley, Andy Burnham, BBC, Biased reporting, competition, David Cameron, Department of Health, Freedom of the Press, government, Health Bill, hospital beds, journalists, Labour Party, Misleading reporting, National Health Service, NHS, non-NHS income, non-NHS work, patient, Patients, Press, private income cap, private patients, Shirley Williams, theatre time, waiting times
6 Comments
Patients to access their own medical records by 2015
Earlier this week during the chancellor of the exchequer’s autumn financial statement, it was announced that not only will patients have online access to their medical records from 2015, but they will be able to see data on GP performance … Continue reading
Posted in Andrew Lansley, competition, Information, Policy
Tagged Andrew lansley, choice, competition, patient
Leave a comment
Parallel importing and exporting of pharmaceuticals severely limits the options in designing an effective UK drug pricing scheme.
A fundamental principle of the EU is the establishment of a single market where products can be freely imported and exported between member states. In the case of pharmaceuticals this ideal conflicts with the freedom of individual countries to fix … Continue reading
Posted in Business, competition, Department of Health, Drugs, Innovation, NHS, Pharma, Policy, Research
Tagged 2020health, competition, Department of Health, Drugs, German pricing, innovation, Lilly, medicine, National Health Service, NHS, NICE, Novartis, parallel exporting, parallel importing, parallel trade, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
1 Comment
Guest Blogspot: NHS Reforms- What the UK Government Policy Changes Really Mean
There is a strong consensus amongst independent experts, medical professionals and politicians that major NHS reforms are both desirable and inevitable. Healthcare is one of mankind’s greatest priorities. An aging population and medical advances mean that healthcare expenditure is bound … Continue reading
Posted in Andrew Lansley, Business, competition, David Cameron, Department of Health, Drugs, Elderly, GPs, Health Bill, Hospitals, NHS, Policy, Research, White Paper
Tagged 2020health, Andrew lansley, cherry picking, Commissioning, competition, David Cameron, Department of Health, elderly, GP, GPs, health, Health and Social Care Bill, Health Bill, Ipsos MORI, National Health Service, NHS, NHS Reforms, Patients, pricing, Quality, R&D, Research
Leave a comment
Comment on Clegg – priority is patient not Party outcomes
In today’s Independent Nick Clegg has set out four demands for changes that will determine whether the Conservatives get the Lib Dems support for the Health Bill. We have the solutions…. Changes demanded by Clegg * “We must ensure that … Continue reading
Posted in competition, Health Bill
Tagged competition, Liberal Democrats, National Health Service, NHS, Nick Clegg, private providers
4 Comments
The NHS has to change
The RCGP has written strongly worded letter to Number 10 about the health bill – it’s all over the news today. Some parts of the government plans are welcomed, such as the greater involvement of GPs in buying and planning … Continue reading
2020health's Blog 
You must be logged in to post a comment.